title: Monocyte-chemoattractant-protein-1-mediated migration of human monocytes towards blasts from patients with acute myeloid leukemia.
abstract: OBJECTIVE
  In the present study the possible clinical relevance of monocyte chemoattractant protein (MCP)-1 in patients with acute myeloid leukemia (AML) was established.
  
  
  METHODS
  The pattern of migration of human monocytes towards the supernatants of blasts from 15 patients with AML was studied and the role of MCP-1, produced by these blasts, was assessed.
  
  
  RESULTS
  In 4 patients (group 1) the amount of monocyte migration was low and not inhibited by the addition of anti-hMCP-1. In 11 patients, the amount of monocyte migration was high; after addition of anti-hMCP-1, monocyte migration was either completely (8 patients, group 2), or partly or not (3 patients, group 3) inhibited to the level of chemokinesis. In groups 1 and 2, there was a good correlation (r = 0.67) between the concentration of MCP-1 in the supernatants and the amount of monocyte migration. In group 3, such a correlation was not evident, suggesting that another chemokine might be involved or MCP-1 function was impaired by an unknown substance. Finally, measurements of MCP-1 during culture of AML blasts showed that the time at which maximal amounts of MCP-1 are produced differs between the AML samples.
  
  
  CONCLUSIONS
  AML blasts produce different amounts of MCP-1, which plays an important role in monocyte migration towards most AML blasts. Therefore, in the context of adoptive immunotherapy, MCP-1 might be involved in future tumor vaccination programmes using autologous MCP-1-transfected irradiated AML blasts.
authors: Department of Hematology, BR 240, University Hospital Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
authors: M C
authors: MC
authors: Legdeur
authors: M G
authors: MG
authors: Broekhoven
authors: G J
authors: GJ
authors: Schuurhuis
authors: R H
authors: RH
authors: Beelen
authors: G J
authors: GJ
authors: Ossenkoppele
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology; D002465:Cell Movement; D018932:Chemokine CCL2 / Q000032:analysis / Q000502:physiology*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000276:immunology* / Q000628:therapy; D009000:Monocytes / Q000502:physiology*
chemical_list: D019496:Cancer Vaccines; D018932:Chemokine CCL2